^
    Back
    Association details:
    Biomarker:ALK fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    09/15/2020
    Excerpt:
    Lorlatinib is a subsequent therapy option for select patients with ALK-positive NSCLC after progression on either alectinib, brigatinib, or certinib depending on the type of progression.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

    Excerpt:
    ...Evidence of histologically or cytologically confirmed diagnosis of locally advanced or metastatic ALK positive NSCLC where ALK status has been previously established by the Ventana ALK (D5F3) CDx Assay (Roche Diagnostics), the Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular), or the EML4 ALK Fusion Gene Detection Kit (AmoyDx)....
    Trial ID:
    NCT03909971
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Lancet Oncol
    Title:

    Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

    Excerpt:
    In ALK-positive patients with at least one previous ALK tyrosine kinase inhibitor (EXP2-5), objective responses were achieved in 93 (47·0%; 39·9-54·2) of 198 patients and objective intracranial response in those with measurable baseline CNS lesions in 51 (63·0%; 51·5-73·4) of 81 patients.
    DOI:
    10.1016/S1470-2045(18)30649-1
    Trial ID:
    NCT01970865